New pneumonia vaccine shows promise in early trial
NCT ID NCT05815264
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage trial tested a new 23-valent pneumococcal polysaccharide vaccine in 144 healthy people aged 2 and older. Participants received one dose of either the experimental or a control vaccine. The study checked for side effects and measured immune response through blood tests. Results will help determine if the vaccine is safe and triggers a strong immune response.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PNEUMONIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Qi County Center for Disease Control and Prevention
Hebi, Henan, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- AI could outsmart bacteria: a smarter way to choose antibiotics?
- Breathing technique may outperform spirometry for smog pneumonia recovery
- A gentle touch against coughs and colds: could manual therapy shorten respiratory illness?
- Can a smart oxygen device shorten hospital stays for pneumonia?
- Could everyday supplements shield your lungs?
- Can a simple inhaled combo keep pneumonia patients off ventilators?